全球热门:招商证券(香港):给予三生制药(01530.HK)“买入”评级 目标价11.00港元

同花顺金融研究中心   2023-02-02 14:44:21


(相关资料图)

招商证券(香港)1月31日发布公告。Wemaintain ourFY22E/23Eearnings projections and SOTP-based TPatHKD11.0.We think Co.’s risk/reward is attractive given 1)Co. tradesat11X/9XFY22E/23E PER, nearthe lowest quantile within its historicalPERband; and 2) in-housepipeline upgradesto trigger potential re-rate(10+ potential NDA approvals/label expansions in 2023E-25E); 3) rich-cash position (~RMB6.5bncash as of June 30) to support BD(10+ dealsin past 3-5years).Keyrisks:ASP erosions fromcompetitions and reimbursement risksetc.